Trials / Completed
CompletedNCT04617314
A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors
A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Effect of RC108-ADC For Injection in Subjects With c-Met Positive Advanced Malignant Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- RemeGen Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety, pharmacokinetics, and effect of RC108-ADC for injeciton in subjects with c-Met positive advanced malignant solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RC108 | RC108 for injection is a novel antibody-drug conjugate, with a c-Met-targeting antibody and a microtube inhibitor. |
Timeline
- Start date
- 2021-03-10
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2020-11-05
- Last updated
- 2026-01-06
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04617314. Inclusion in this directory is not an endorsement.